GlassScriptPhysician profile
Sarah Therese Mcguire
NPI 1417163601
$2,093.88
in general payments reported to CMS, 2019-2025
18 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.00 · 2020: $44.92 · 2021: $103 · 2022: $742 · 2023: $426 · 2024: $301 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,188.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $378.49 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $357.48 | 2021-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $205.57 | 2022-2025 | Invega Sustenna |
| Alkermes, INC. | $163.92 | 2023-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $162.89 | 2020-2025 | Caplyta |
| Corium, LLC | $141.60 | 2022-2025 | Azstarys |
| Lundbeck LLC | $140.54 | 2020-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $90.99 | 2022-2023 | Trintellix |
| Neos Therapeutics, LP | $90.51 | 2021-2023 | Adzenys Xr-Odt |
| Axsome Therapeutics, INC. | $85.11 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $53.70 | 2022-2023 | Austedo |
| Vanda Pharmaceuticals INC. | $51.32 | 2019-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $46.39 | 2021-2025 | Qelbree |
| Collegium Pharmaceutical, INC. | $46.33 | 2025 | Jornay Pm |
| Tris Pharma INC | $25.73 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $23.90 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $14.73 | 2021 | |
| Allergan, INC. | $14.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Mcguire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.